Hoersholm, Denmark, 30 September 2015
Oncology Venture announces that it has incorporated the APO010 Drug Response Predictor – (APO010 DRPTM) from MPI A/S into its clinical development program. Based on the DRP it has been decided to develop APO010 into the treatment of multiple myeloma. The DRPTM will consequently be used in the screening of Multiple Myeloma patients in a phase 1b/2 program, which is planned to be initiated in Q4 2015 as a multi-center study at hematology departments in Denmark. The purpose of the screening is to find the screening is to select the patients with the highest likelihood to respond to APO010.